Surgical Resection of Latent Brain Tumors Prior to Recurrence
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT04810871
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Brain Surgery — PROCEDUREUndergo surgery
Study Details
This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.
Key Dates
- First listed
- Mar 23, 2021
- Start date
- May 6, 2021
- Status verified
- Oct 2026
- Primary completion
- Mar 1, 2028
- Completion
- Mar 1, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (surgery)Patients undergo surgery as indicated clinically when applicable.
Primary Outcome Measure
Feasibility of surgical resection by short and long term outcomes [ Time Frame: Up to 5 years ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Terry C. Burns, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Tumor Related EpilepsyRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain TumorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York